PHILADELPHIA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics, Inc., a clinical-stage immunotherapy company pioneering innovative cell therapies, today announced it will share interim clinical data from its Phase 1 first-in-human study of VIPER-101, a CD5-modulated autologous CAR-T therapy for patients with relapsed or refractory (r/r) T-cell lymphoma (TCL), in…
Read More
Vittoria Biotherapeutics to Share Trials-in-Progress Presentation from Phase 1 Study of VIPER-101 at ASCO 2025 Annual Meeting Trial is evaluating VIPER-101, a novel, gene-edited, autologous dual-population CAR-T therapy in patients with T-cell lymphoma PHILADELPHIA, May 28, 2025 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics Inc., a clinical-stage immunotherapy company specializing in the development of innovative…
Read More
Vittoria Biotherapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of VIPER-101 Trial is evaluating VIPER-101, a novel, gene edited, autologous dual-population CAR-T therapy in patients with T cell lymphoma VIPER-101 was developed with Vittoria’s proprietary Senza5 platform that features CD5 modulation and a proprietary 5-day manufacturing…
Read More